复发难治性非霍奇金淋巴瘤治疗进展

Recurrence of the recent advances in the treatment of refractory non-hodgkin's lymphoma

在肿瘤临床研究方面,淋巴瘤是一种异质性的疾病,淋巴瘤在临床表现、分子生物学、治疗的疗效、病状的转归都有较大的差异。本研究主要针对复发难治性非霍奇金淋巴瘤(NHL)治疗进展进行探讨与研究。就目前而言,复发非霍奇金淋巴瘤治疗在生物学上不断取得新的进展,并且受到了世界卫生组织新分类标准的认可。在淋巴瘤治疗新药物的不断研发和治疗方案不断改进的过程中,对淋巴瘤患者的治愈率也有进一步提高。由于淋巴瘤的异质性,致使对非霍奇金淋巴瘤患者的治疗存在一定的多样性以及复杂性,所以研究复发难治性非霍奇金淋巴瘤治疗进展对临床医学具有重要意义。

In cancer clinical research, lymphoma is a heterogeneous disease, lymphoma in clinical manifestation, molecular biol- ogy, and the curative effect of treatment, symptom of outcome there are great differences. This research mainly for recurrence refrac- tory non - hodgking lymphoma （NHL） treatment progress were discussed and analyzed. For the moment, recurrence non - hodgking lymphoma treatment in biology have made great progress, and by the world health organization new classification standard approval. In lymphoma treatment of new drugs are continuously developed and treatment in the process of continuous improvement, the lymphoma patients also have further improve the cure rate. Due to the heterogeneity of lymphoma, cause for the treatment of non - hodgkin lym- phoma patients, there are certain diversity and complexity, so the recurrence of the recent advances in the treatment of refractory non - hodgking lymphoma of clinical medicine is of great significance.